INDEPENDENT clinical trials of new cancer therapies are threatened by the market-style changes to the NHS, says the UK Co-ordinating Committee on Cancer Research - an independent group representing researchers. It says there is now a greater reliance on trials paid for by drug companies.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments